Home › Auto-immuunziekten › North Carolina › Durham
Auto-immuunziekten klinische studies in Durham, NC
15 studies voor Auto-immuunziekten zoeken deelnemers op locaties in en rond Durham (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Environmental Risk Factors for the Anti-synthetase Syndrome
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- NIEHS Clinical Research Unit (CRU), Research Triangle Park · 7 mijl verwijderd
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruterenFase 3
- Duke University Hospital, Durham
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RekruterenFase 2/3
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill · 10 mijl verwijderd
Daratumumab in Primary Antiphospholipid Syndrome
RekruterenFase 1/2
- Duke University, Durham
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RekruterenFase 1
- Duke University Medical Center, Durham
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruterenFase 3
- Duke University Hospital, Durham
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RekruterenFase 3
- GSK Investigational Site, Durham
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RekruterenFase 1/2
- UNC Chapel Hill, Chapel Hill · 10 mijl verwijderd
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RekruterenFase 2/3
- Duke University, Durham
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
RekruterenFase 3
- Duke University Medical Center, Durham
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RekruterenFase 3
- Site Number - 1013, Durham
- Site Number - 1020, Chapel Hill · 10 mijl verwijderd
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RekruterenFase 1
- Duke University, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruterenObservatieonderzoek
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mijl verwijderd
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RekruterenFase 1
- Duke University Health System, Durham
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Duke University, Durham
Auto-immuunziekten studies in andere steden
- Houston, TX21 studies
- Washington, DC19 studies
- New York City, NY19 studies
- Philadelphia, PA16 studies
- Boston, MA13 studies
- Los Angeles, CA12 studies
- Chicago, IL12 studies
- Dallas, TX9 studies
- Cleveland, OH8 studies
- Milwaukee, WI8 studies
- Atlanta, GA8 studies
- Portland, OR8 studies
Andere studies in Durham
- Borstkanker63 studies
- Kanker (alle vormen)58 studies
- Niet-kleincellige longkanker39 studies
- Multipel myeloom37 studies
- Metastatische kanker33 studies
- Acute myeloïde leukemie33 studies
- Longkanker32 studies
- Prostaatkanker32 studies
- Colorectale kanker28 studies
- Chronische lymfatische leukemie27 studies
- Eierstokkanker27 studies
- Hartfalen26 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.